GEP20257739B - Pediatric trazodone compositions - Google Patents
Pediatric trazodone compositionsInfo
- Publication number
- GEP20257739B GEP20257739B GEAP202015936A GEAP2020015936A GEP20257739B GE P20257739 B GEP20257739 B GE P20257739B GE AP202015936 A GEAP202015936 A GE AP202015936A GE AP2020015936 A GEAP2020015936 A GE AP2020015936A GE P20257739 B GEP20257739 B GE P20257739B
- Authority
- GE
- Georgia
- Prior art keywords
- trazodone
- pediatric
- compositions
- ndd
- insomnia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962906166P | 2019-09-26 | 2019-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP20257739B true GEP20257739B (en) | 2025-02-25 |
Family
ID=72665264
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP202015936A GEP20257739B (en) | 2019-09-26 | 2020-09-25 | Pediatric trazodone compositions |
| GEAP202415936A GEAP202415936A (en) | 2019-09-26 | 2020-09-25 | Pediatric trazodone compositions |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP202415936A GEAP202415936A (en) | 2019-09-26 | 2020-09-25 | Pediatric trazodone compositions |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12514856B2 (enExample) |
| EP (1) | EP4034117A1 (enExample) |
| JP (1) | JP7629453B2 (enExample) |
| KR (1) | KR102936358B1 (enExample) |
| CN (1) | CN114615983A (enExample) |
| AU (1) | AU2020354534B2 (enExample) |
| BR (1) | BR112022005343A2 (enExample) |
| CA (1) | CA3153639A1 (enExample) |
| GE (2) | GEP20257739B (enExample) |
| IL (1) | IL291548A (enExample) |
| MX (1) | MX2022003442A (enExample) |
| UA (1) | UA129270C2 (enExample) |
| WO (1) | WO2021058810A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240173315A1 (en) * | 2022-11-14 | 2024-05-30 | OWP Pharmaceuticals, Inc. | Trazodone oral solution |
| US20240390277A1 (en) * | 2023-04-15 | 2024-11-28 | Rubicon Research Private Limited | Liquid formulations of trazodone |
| CN119280155B (zh) * | 2024-12-11 | 2025-02-25 | 新基元(北京)医药科技有限公司 | 一种改善稳定性的盐酸曲唑酮液体药物组合物及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1931346T1 (sl) | 2005-09-09 | 2012-10-30 | Angelini Labopharm Llc | Trazodonski sestavek za dajanje enkrat dnevno |
| ITMI20071573A1 (it) * | 2007-07-31 | 2009-02-01 | Acraf | Composizione farmaceutica liquida stabile a base di trazodone |
| ITMI20071603A1 (it) | 2007-08-03 | 2009-02-04 | Acraf | Trazodone e trazodone cloridrato in forma purificata |
-
2020
- 2020-09-25 MX MX2022003442A patent/MX2022003442A/es unknown
- 2020-09-25 UA UAA202201314A patent/UA129270C2/uk unknown
- 2020-09-25 AU AU2020354534A patent/AU2020354534B2/en active Active
- 2020-09-25 CA CA3153639A patent/CA3153639A1/en active Pending
- 2020-09-25 GE GEAP202015936A patent/GEP20257739B/en unknown
- 2020-09-25 KR KR1020227011618A patent/KR102936358B1/ko active Active
- 2020-09-25 EP EP20781357.7A patent/EP4034117A1/en active Pending
- 2020-09-25 JP JP2022518971A patent/JP7629453B2/ja active Active
- 2020-09-25 WO PCT/EP2020/077017 patent/WO2021058810A1/en not_active Ceased
- 2020-09-25 BR BR112022005343A patent/BR112022005343A2/pt unknown
- 2020-09-25 GE GEAP202415936A patent/GEAP202415936A/en unknown
- 2020-09-25 CN CN202080066712.7A patent/CN114615983A/zh active Pending
- 2020-09-25 US US17/763,037 patent/US12514856B2/en active Active
-
2022
- 2022-03-21 IL IL291548A patent/IL291548A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022549473A (ja) | 2022-11-25 |
| IL291548A (en) | 2022-05-01 |
| JP7629453B2 (ja) | 2025-02-13 |
| CA3153639A1 (en) | 2021-04-01 |
| GEAP202415936A (en) | 2024-10-28 |
| WO2021058810A1 (en) | 2021-04-01 |
| MX2022003442A (es) | 2022-07-11 |
| BR112022005343A2 (pt) | 2022-06-14 |
| US12514856B2 (en) | 2026-01-06 |
| KR102936358B1 (ko) | 2026-03-10 |
| EP4034117A1 (en) | 2022-08-03 |
| KR20220080096A (ko) | 2022-06-14 |
| US20220331312A1 (en) | 2022-10-20 |
| UA129270C2 (uk) | 2025-03-05 |
| AU2020354534B2 (en) | 2025-10-02 |
| CN114615983A (zh) | 2022-06-10 |
| AU2020354534A1 (en) | 2022-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEAP202415936A (en) | Pediatric trazodone compositions | |
| PH12019501074A1 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| MX2023002004A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| EP4706761A3 (en) | Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders | |
| PH12018502378A1 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| EP4487908A3 (en) | Methods of treating crohn's disease and ulcerative colitis | |
| MY155255A (en) | Spiro-oxindole compounds and their use as therapeutic agents | |
| MX2025008327A (es) | Composiciones y metodos para el tratamiento de trastornos del snc | |
| EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
| PH12021550381A1 (en) | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | |
| PH12020552111A1 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| EP3970712A3 (en) | Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof | |
| MX2024003952A (es) | Combinación que comprende atogepant para tratar la migraña. | |
| MX2020008816A (es) | Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas. | |
| WO2010132352A3 (en) | Spiro compounds and their use as therapeutic agents | |
| PH12020551772A1 (en) | Oxo-substituted compound | |
| MX384745B (es) | Proceso para la preparación de compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidina-2,7-diona 3-sustituidos. | |
| MY201041A (en) | Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group ii metabotropic glutamate receptor | |
| MX2018000240A (es) | Metodos para tratar el vhc. | |
| MX2020007817A (es) | Prevención y tratamiento del trastorno del sueño. | |
| MX2022012632A (es) | Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington. | |
| MX2020009334A (es) | Compuestos para tratar la enfermedad de alzheimer. | |
| WO2014193269A3 (ru) | Лекарственное средство на основе дииндолилметана и его применение для лечения гриппа и респираторных вирусных инфекций |